PFE and The Global Demographic Tailwind: http://finance.yahoo.com/news/pfizers-ceo-discusses-q1-2013-165608862.html During the first quarter, biopharmaceutical volume [grew]10% in the BRIC-MT* markets…primarily driven by strong growth in China and partially offset by price reductions of 1% to these markets… If you exclude the product portfolio of products whose rights were transferred to our joint venture in China with Hisun, our operational revenue growth would have been 8% in our emerging markets business, 14% in BRIC-MT countries and 31% in China. *Brazil, Russia, India, China, Mexico, Turkey.